Research ExplorerPublicationsCirculating Tumour DNA Is a Strong Predictor of Outcomes in ...

Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma

Standard

Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. / Laukhtina, Ekaterina; Hassler, Melanie R; Pradere, Benjamin; Yanagisawa, Takafumi; Quhal, Fahad; Rajwa, Pawel; Sari Motlagh, Reza; König, Frederik; Pallauf, Maximilian; Kawada, Tatsushi; Mostafaei, Hadi; D'Andrea, David; Enikeev, Dmitry; Shariat, Shahrokh F.

In: EUR UROL FOCUS, Vol. 8, No. 6, 11.2022, p. 1683-1686.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Laukhtina, E, Hassler, MR, Pradere, B, Yanagisawa, T, Quhal, F, Rajwa, P, Sari Motlagh, R, König, F, Pallauf, M, Kawada, T, Mostafaei, H, D'Andrea, D, Enikeev, D & Shariat, SF 2022, 'Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma', EUR UROL FOCUS, vol. 8, no. 6, pp. 1683-1686. https://doi.org/10.1016/j.euf.2022.04.017

APA

Laukhtina, E., Hassler, M. R., Pradere, B., Yanagisawa, T., Quhal, F., Rajwa, P., Sari Motlagh, R., König, F., Pallauf, M., Kawada, T., Mostafaei, H., D'Andrea, D., Enikeev, D., & Shariat, S. F. (2022). Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. EUR UROL FOCUS, 8(6), 1683-1686. https://doi.org/10.1016/j.euf.2022.04.017

Vancouver

Laukhtina E, Hassler MR, Pradere B, Yanagisawa T, Quhal F, Rajwa P et al. Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. EUR UROL FOCUS. 2022 Nov;8(6):1683-1686. https://doi.org/10.1016/j.euf.2022.04.017

Bibtex

@article{9c52c604f06a4b70a6094104fc772732,
title = "Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma",
abstract = "We summarise the available data for and assess the prognostic value of circulating tumour DNA (ctDNA) in patients treated with systemic therapy for urothelial carcinoma (UC). Studies were deemed eligible if they reported on oncologic outcomes for patients with UC treated with systemic therapy according to the baseline ctDNA profile (before starting systemic therapy) and/or changes over the course of therapy. Five studies met the eligibility criteria. We found a strong association between high baseline ctDNA levels and worse disease-free survival (DFS; hazard ratio [HR] 3.53, 95% confidence interval [CI] 2.58-4.84) and overall survival (OS; HR 2.99, 95% CI 2.17-4.13). Patients with a decline in ctDNA level after immunotherapy had better DFS (HR 0.25, 95% CI 0.13-0.49) and OS (HR 0.10, 95% CI 0.03-0.42) in comparison to patients without a ctDNA decline. Conversely, an increase in ctDNA levels after immunotherapy was associated with worse survival outcomes. Patients with UC who exhibited a decrease in ctDNA levels during systemic therapy had better survival outcomes compared to those with stable or increasing ctDNA levels. PATIENT SUMMARY: Measurement of tumour DNA in blood may help in identifying patients with cancer of the urinary tract who are unlikely to respond to chemotherapy or immunotherapy. This could serve as a biomarker for monitoring cancer treatment.",
keywords = "Humans, Carcinoma, Transitional Cell/drug therapy, Urinary Bladder Neoplasms/drug therapy, Circulating Tumor DNA/genetics",
author = "Ekaterina Laukhtina and Hassler, {Melanie R} and Benjamin Pradere and Takafumi Yanagisawa and Fahad Quhal and Pawel Rajwa and {Sari Motlagh}, Reza and Frederik K{\"o}nig and Maximilian Pallauf and Tatsushi Kawada and Hadi Mostafaei and David D'Andrea and Dmitry Enikeev and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2022 The Author(s). Published by Elsevier B.V. All rights reserved.",
year = "2022",
month = nov,
doi = "10.1016/j.euf.2022.04.017",
language = "English",
volume = "8",
pages = "1683--1686",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "6",

}

RIS

TY - JOUR

T1 - Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma

AU - Laukhtina, Ekaterina

AU - Hassler, Melanie R

AU - Pradere, Benjamin

AU - Yanagisawa, Takafumi

AU - Quhal, Fahad

AU - Rajwa, Pawel

AU - Sari Motlagh, Reza

AU - König, Frederik

AU - Pallauf, Maximilian

AU - Kawada, Tatsushi

AU - Mostafaei, Hadi

AU - D'Andrea, David

AU - Enikeev, Dmitry

AU - Shariat, Shahrokh F

N1 - Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

PY - 2022/11

Y1 - 2022/11

N2 - We summarise the available data for and assess the prognostic value of circulating tumour DNA (ctDNA) in patients treated with systemic therapy for urothelial carcinoma (UC). Studies were deemed eligible if they reported on oncologic outcomes for patients with UC treated with systemic therapy according to the baseline ctDNA profile (before starting systemic therapy) and/or changes over the course of therapy. Five studies met the eligibility criteria. We found a strong association between high baseline ctDNA levels and worse disease-free survival (DFS; hazard ratio [HR] 3.53, 95% confidence interval [CI] 2.58-4.84) and overall survival (OS; HR 2.99, 95% CI 2.17-4.13). Patients with a decline in ctDNA level after immunotherapy had better DFS (HR 0.25, 95% CI 0.13-0.49) and OS (HR 0.10, 95% CI 0.03-0.42) in comparison to patients without a ctDNA decline. Conversely, an increase in ctDNA levels after immunotherapy was associated with worse survival outcomes. Patients with UC who exhibited a decrease in ctDNA levels during systemic therapy had better survival outcomes compared to those with stable or increasing ctDNA levels. PATIENT SUMMARY: Measurement of tumour DNA in blood may help in identifying patients with cancer of the urinary tract who are unlikely to respond to chemotherapy or immunotherapy. This could serve as a biomarker for monitoring cancer treatment.

AB - We summarise the available data for and assess the prognostic value of circulating tumour DNA (ctDNA) in patients treated with systemic therapy for urothelial carcinoma (UC). Studies were deemed eligible if they reported on oncologic outcomes for patients with UC treated with systemic therapy according to the baseline ctDNA profile (before starting systemic therapy) and/or changes over the course of therapy. Five studies met the eligibility criteria. We found a strong association between high baseline ctDNA levels and worse disease-free survival (DFS; hazard ratio [HR] 3.53, 95% confidence interval [CI] 2.58-4.84) and overall survival (OS; HR 2.99, 95% CI 2.17-4.13). Patients with a decline in ctDNA level after immunotherapy had better DFS (HR 0.25, 95% CI 0.13-0.49) and OS (HR 0.10, 95% CI 0.03-0.42) in comparison to patients without a ctDNA decline. Conversely, an increase in ctDNA levels after immunotherapy was associated with worse survival outcomes. Patients with UC who exhibited a decrease in ctDNA levels during systemic therapy had better survival outcomes compared to those with stable or increasing ctDNA levels. PATIENT SUMMARY: Measurement of tumour DNA in blood may help in identifying patients with cancer of the urinary tract who are unlikely to respond to chemotherapy or immunotherapy. This could serve as a biomarker for monitoring cancer treatment.

KW - Humans

KW - Carcinoma, Transitional Cell/drug therapy

KW - Urinary Bladder Neoplasms/drug therapy

KW - Circulating Tumor DNA/genetics

U2 - 10.1016/j.euf.2022.04.017

DO - 10.1016/j.euf.2022.04.017

M3 - SCORING: Review article

C2 - 35562252

VL - 8

SP - 1683

EP - 1686

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

IS - 6

ER -